Alterity医疗 ATHE 深 沪
等待开盘 04-01 09:30:00 美东时间
3.48
-0.090
-2.52%
华盛通- 最 高3.57
- 今 开3.41
- 成交量 4448股
- 最 低 3.41
- 昨 收 3.57
- 总市值 6307.74万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 2.66
- 委 比 33.33%
- 总股本 1812.57万
- 历史最高 51.50
- 量 比 0.19
- 振 幅 4.48%
- 历史最低 1.001
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Flags Risks Around Forward‑Looking Corporate Outlook
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
今天 13:28
Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received
03-30 19:26
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alterity Therapeutics announced positive feedback from the FDA after a Type C Meeting regarding its Phase 3 development program for ATH434 in treating Multiple System Atrophy (MSA). The feedback supports the clinical pharmacology and non-clinical elements of the program. Alterity plans to seek agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, aiming for an End-of-Phase 2 meeting in mid-2026. ATH4...
03-30 11:25
Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therap...
03-09 08:52
Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor
Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor Alterity Therapeutics Ltd. has appointed Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, with the role starting in March 2026. Claassen will retain his academic appointment at Vanderbilt University Medical Center wh
03-04 19:04
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
Alterity Therapeutics appoints Daniel O. Claassen, M.D., as Chief Medical Advisor to enhance expertise in neurodegenerative diseases, particularly Multiple System Atrophy (MSA). With over two decades of experience in movement disorders and clinical trials, Dr. Claassen will guide the Phase 3 trial for ATH434, building on his role as coordinating investigator in the Phase 2 study. Alterity, a biotech focused on neurodegenerative treatments, antici...
03-04 12:25
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics provided an update on its activities for Q2 FY26, highlighting advancements in its MSA program, Phase 2 data strengthening, and planning for a pivotal Phase 3 trial. The company presented additional analyses of the Phase 2 trial at international congresses, including improved efficacy signals for ATH434 at the 75 mg dose. Regulatory planning for an End-of-Phase 2 meeting with the FDA in mid-2026 is progressing, with a focus ...
01-30 12:25
Alterity Targets $2.4B Market as Lead Drug Clears Phase 2 and Moves Toward Phase 3
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to
01-21 20:27
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Alterity Therapeutics (ATH) achieved Phase 2 success for ATH434 in treating Multiple System Atrophy (MSA), demonstrating safety, efficacy, and disease progression slowing. Results position the company for Phase 3 planning and potential entry into a $2.4B market. Key 2026 milestones include FDA-end-of-Phase 2 meeting, expanding engagement, and scaling infrastructure. The company also strengthened its leadership team to support growth. Alterity rem...
01-21 12:25
Alterity Flags Risk Context for Forward-Looking Statements in 2026 Presentation
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
01-13 08:18
